Please ensure Javascript is enabled for purposes of website accessibility

Why ShockWave Medical Stock Is Sinking Today

By Keith Speights – Updated Apr 1, 2020 at 12:07PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

An analyst downgrade sparked a sell-off of the medical device maker.

What happened

Shares of ShockWave Medical (SWAV -2.61%) were sinking 14.5% as of 11:43 a.m. EDT on Wednesday. The drop came after Oppenheimer analyst Suraj Kalia downgraded the medical device stock to an underperform rating with a one-year price target 31% lower than ShockWave's closing price on Tuesday.

So what

Wall Street analysts' downgrades (and upgrades) should be taken with a grain of salt. There's a built-in incentive for analysts to focus on the short term rather than the long term. 

Man with hands on top of his head with a stock chart showing a decline in the background

Image source: Getty Images.

It's certainly possible that ShockWave's short-term prospects could be dented somewhat in the wake of the coronavirus pandemic. Some less-crucial procedures could be pushed back. But any such delays will only be temporary. No physician or patient will want to postpone procedures using ShockWave's intravascular lithotripsy (IVL) for too long.

And ShockWave's long-term prospects still appear to be very good. IVL is less risky than using balloons or performing surgery to clear plaque buildup in arteries. CEO Doug Godshall even mentioned in the company's Q4 conference call in February that "IVL has surprised us by being used effectively in ways we had not thought possible, and ways that make a huge difference in treating patients."

Now what

ShockWave's outlook provided in February projected full-year 2020 revenue between $74 million and $77 million. The midpoint of that range represents year-over-year growth of more than 75%. Investors will want to monitor if the company backtracks any on that guidance in light of the pandemic. 

Even healthcare stocks like ShockWave that should be largely insulated from the effects of the pandemic will probably remain very volatile for at least another couple of months. But this could present tremendous buying opportunities for investors who have a long-term perspective and shrug off negative takes from analysts who don't.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends ShockWave Medical. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

ShockWave Medical Stock Quote
ShockWave Medical
$252.08 (-2.61%) $-6.76

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.